Until recently, she was Senior Vice President, Business Development at Corixa, a biotech company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases. She joined Coulter Pharmaceutical, Inc. in October 1996 as Vice President of Business Development, which was acquired by Corixa in December 2000. While at Corixa/Coulter she completed numerous transactions including the $1.0B merger between the companies and a contractual JV with GSK for Bexxar valued in excess of $200M. Mrs. Morris was Vice President of Business Development at Scios Inc. between 1993-6. She completed several high profile transactions including one of the first Biotech profit sharing deals for a late-stage product. From 1977-1993, she held various management and executive positions at Johnson & Johnson in sales, marketing and business development, holding the position of Vice President of Business Development for McNeil Pharmaceuticals from 1988-93. She received her B.A. degree from Carlow College, and completed graduate studies in marketing at Western New England College. She is a member of the Board of Directors of the Licensing Executives Society.  

Dr. Rivka Sherman-Gold joined Alydar in 2001 as President and Chief Executive Officer, bringing with her 17 years of experience in the biopharmaceutical industry. Prior to joining Alydar, Dr. Sherman-Gold was at Abgenix, Inc. where she served as Director of Business Development since 1996. In that position, Dr. Sherman-Gold was responsible for the business development growth of Abgenix from its start-up stage as a spin-out from Cell Genesys to a successful publicly traded billion-dollar leading biotechnology company. Dr. Sherman-Gold initiated and negotiated licensing and partnership agreements, and managed the transactions and relationships, with more than 15 leading pharmaceutical and biotechnology firms, including Pfizer, Schering-Plough, Amgen, SmithKline Beecham (GlaxoSmithKline), Elan, Chiron, Millennium BioTherapeutics (Millennium Pharmaceuticals), and Centocor (Johnson & Johnson). From 1993 to 1996, Dr. Sherman-Gold was Associate Director of Business Development at Athena Neurosciences, Inc. (acquired in 1996 by Elan Corporation). From 1989 to 1993, she held various positions at Axon Instruments, Inc., most recently serving as Director of Marketing and Scientific Applications. Dr. Sherman-Gold was a recipient of the Chaim Weizmann Postdoctoral Fellowship, the National Amyotrophic Lateral Sclerosis (NALS) Postdoctoral Fellowship, and the Syntex Community Service Award for founding and serving as the first president of the Bay Area chapter of the Association for Women in Science (AWIS Palo Alto). Dr. Sherman-Gold holds a B.Sc. with honors in chemistry and M.Sc. in physiology and biophysics from the Technion - Israel Institute of Technology in Haifa, Israel, and a Ph.D. in life sciences from the Weizmann Institute of Science in Rehovot, Israel. She completed a postdoctoral fellowship at Stanford University School of Medicine and earned an M.B.A. from California State University, San Jose.  

Camille Samuels Pearson joined Versant Ventures in March of 2000. At Versant, she has been actively involved in Versant's investments in Fluidigm, Genomic Health, ParAllele Genomics, Reliant Pharmaceuticals, and Syrrx. Prior to Versant, Camille was a director of business development at Tularik Inc. At Tularik, Camille was responsible for corporate strategy and developing partnerships around clinical/preclinical therapeutic programs. She also led Tularik's Technology Acquisition Group, a group that was charged with keeping the company at the leading edge in platform technologies. During her tenure at Tularik, the company grew from a small, venture-funded company to a billion-dollar public company with comprehensive research and development capabilities. Before Tularik, Camille helped develop the business and marketing plan for the Predictive Medicine division of Millennium Pharmaceuticals. She also worked in strategy and business development for Genzyme Corporation. Camille started her career as an Associate Consultant with LEK Consulting, providing management consulting and M&A advisory services to private equity and healthcare clients. Camille earned her Bachelor's degree in Biology from Duke University and an MBA from Harvard Business School, where she graduated as a Baker Scholar.  

Dr. Rabson joined Maxygen in September 1999. Prior to joining Maxygen, from February 1996 to September 1999, Dr. Rabson was a Partner in the Technology Transactions Group at Wilson Sonsini Goodrich & Rosati, P.C. where he had previously been an associate. Dr. Rabson received his Ph.D. in infectious disease epidemiology from Yale University and did a post-doctoral fellowship at the National Cancer Institute, National Institutes of Health. He was a patent examiner at the U.S. Patent and Trademark Office before he received his J.D. from Yale Law School.